Gastrointestinal oncology
Oncomatryx Biopharma S.L. is focused on advanced and metastatic colorectal cancer, with particular interest in microsatellite-stable disease and treatment-resistant settings after prior systemic therapy.
- Metastatic colorectal cancer
- Regorafenib-based combinations
- Immune checkpoint inhibition
The company’s clinical work in this area centers on tumor control in heavily pretreated disease and on combination strategies that integrate targeted and immuno-oncology agents.
Thoracic oncology
Its research portfolio includes advanced non-squamous non-small cell lung cancer, with attention to metastatic disease requiring multi-agent treatment approaches.
- Non-small cell lung cancer
- Platinum-based chemotherapy combinations
- Tislelizumab
Clinical activity in this field reflects interest in combining antibody-drug conjugate strategies with established lung cancer regimens to address advanced solid tumors.
Pancreatic cancer
The sponsor also studies advanced pancreatic adenocarcinoma, a disease with limited treatment options and a strong need for new systemic therapies.
- Metastatic pancreatic adenocarcinoma
- Solid tumor immunotherapy combinations
- Stromal-targeted oncology
This area aligns with interest in tumors characterized by a dense tumor microenvironment and resistance to conventional treatment.
Fibroblast activation protein–expressing tumors
Another key area is FAP-expressing malignancies, including carcinomas with cancer-associated fibroblasts and selected sarcomas with tumor-cell expression of the target.
- FAP-positive solid tumors
- Leiomyosarcoma
- Other sarcomas
These studies indicate a therapeutic interest in stromal targeting across tumor types where fibroblast activation protein is a relevant biological marker.
